Table 1 Summary of response of the different clinical outcomes.
| Outcome measure | Baseline | Week 4 | p Value | Week 20 | p Value |
|---|---|---|---|---|---|
| VAS physician global assessment (mm) | 57 (45–90) | 27.5 (2–77) | 0.001 | 17.5 (0–61) | 0.000 |
| VAS patient disease activity (mm) | 59 (21–94) | 21 (3–68) | 0.001 | 20.5 (0–71) | 0.001 |
| VAS pain (mm) | 63.5 (22–96) | 24.5 (5–65) | 0.001 | 25.5 (0–78) | 0.003 |
| HAQ | 16.5 (6–23) | 11 (3–22) | <0.001 | 12 (0–22) | 0.000 |
| Tender joint count (68) | 14.5 (0–73) | 7 (0–65) | 0.008 | 5 (0–43) | 0.002 |
| Swollen joint count (66) | 7.5 (4–46) | 1 (0–9) | <0.001 | 0 (0–5) | 0.000 |
| EMS (min) | 120 (10–240) | 30 (0–120) | 0.002 | 20 (0–90) | 0.000 |
| CRP (mg/l) | 18.5 (2–124) | <5 (<5–10) | <0.001 | <5 (0–11) | 0.000 |
| PASI | 1.8 (0–28.1) | 0.6 (0–16.7) | 0.001 | 0 (0–13.5) | 0.003 |
| PsAQoL | 13 (<5–19) | 12 (2–19) | 0.484 | 10 (0–15) | 0.006 |
CRP, C reactive protein; EMS, early morning stiffness; HAQ, Health Assessment Questionnaire; PASI, Psoriatic Area and Severity Index; PsAQoL, Psoriatic Arthritis Quality of Life; VAS, visual analogue scale.
Values are given as median (range).